Comparision of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

M.G. Bousser, J. Bouthier, H.R. Buller, A.T. Cohen, H. Crijns, B.L. Davidson, J. Halperin, Graeme Hankey, S. Levy, V. Pengo, P. Prandoni, M.H. Prins, W. Tomkowski, C. Thorp-Pedersen, D.G. Wyse

    Research output: Contribution to journalArticlepeer-review

    252 Citations (Scopus)

    Abstract

    Background: Vitamin K antagonists, the current standard treatment for prophylaxis against stroke and systemic embolism in patients with atrial fibrillation, require regular monitoring and dose adjustment; an unmonitored, fixed-dose anticoagulant regimen would be preferable. The aim of this randomised, open-label non-inferiority trial was to compare the efficacy and safety of idraparinux with vitamin K antagonists. Methods: Patients with atrial fibrillation at risk for thromboembolism were randomly assigned to receive either subcutaneous idraparinux (2·5 mg weekly) or adjusted-dose vitamin K antagonists (target of an international normalised ratio of 2–3). Assessment of outcome was done blinded to treatment. The primary efficacy outcome was the cumulative incidence of all stroke and systemic embolism. The principal safety outcome was clinically relevant bleeding. Analyses were done by intention to treat; the non-inferiority hazard ratio was set at 1·5. This trial is registered with ClinicalTrials.gov, number NCT00070655. Findings: The trial was stopped after randomisation of 4576 patients (2283 to receive idraparinux, 2293 to receive vitamin K antagonists) and a mean follow-up period of 10·7 (SD 5·4) months because of excess clinically relevant bleeding with idraparinux (346 cases vs 226 cases; 19·7 vs 11·3 per 100 patient-years; p
    Original languageEnglish
    Pages (from-to)315-321
    JournalThe Lancet
    Volume371
    Issue number9609
    DOIs
    Publication statusPublished - 2008

    Fingerprint

    Dive into the research topics of 'Comparision of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial'. Together they form a unique fingerprint.

    Cite this